Vaginal Slings Market Analysis

In-depth Analysis of Vaginal Slings Market Industry Landscape

The US Food and Drug Administration (FDA) deems the mid-urethral sling as a safe and effective treatment, boasting an approximately 80% cure rate for stress urinary incontinence (SUI) in women. The preferred surgical approach involves synthetic mid-urethral sling placement, showcasing high comparative efficiency and cost-effectiveness within the healthcare system. The current minimally invasive surgical techniques, including innovations like MiniArc (American Medical Systems, Inc) and TVT-O, contribute to the success of these procedures. Manufacturers continually invest in research and development to enhance their products and gain a competitive edge. While healthcare organizations, such as the National Institute on Aging, support research for urinary incontinence treatment, specific device development remains unfunded. Growing R&D activities and increased support from healthcare organizations are anticipated to foster the global vaginal slings market.

The aging population's rise escalates the demand for mid-urethral sling devices due to increased instances of urinary incontinence linked to chronic conditions prevalent in the elderly, such as bladder, liver, and kidney diseases. Stress incontinence, particularly in women, becomes more common as pelvic floor and urinary sphincter muscles weaken with age. According to the United Nations' World Population Ageing 2017 report, women aged 60 years or over constituted 54% of the global population in 2017. This condition is often observed during pregnancy and childbirth. With the aging population on the rise, cases of urinary incontinence requiring treatments like sling surgeries among women present substantial opportunities for market vendors. Key countries with the most aged populations include Japan, South Korea, China, Germany, Israel, and the US. As the aging population expands, urologists face challenges in managing diseases like Benign Prostatic Obstruction (BPO) in the elderly, potentially increasing the risk of surgical complications. Studies suggest that a significant percentage of patients with Lower Urinary Tract Side-Effects (LUTS) may not achieve satisfactory improvement with lifestyle modifications alone. Despite being considered the gold standard, transurethral resection of the prostate (TURP) poses mortality and morbidity risks. With increasing mortality and morbidity rates for urinary infections, the global urinary incontinence market is expected to grow in the future.